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integration of both quantity and quality of life into a single
analysis to be used for treatment comparisons. METHODS:
EORTC QLQ C-30, FACT-G&P were used to collect
QoL data for 288 subjects with asymptomatic hormone
refractory prostate cancer as part of a randomized, dou-
ble-blind, placebo-controlled dose ranging study of atra-
sentan, a selective endothelin-A receptor antagonist. Both
instruments were administered at baseline and then at ev-
ery six weeks until disease progression. The missing QoL
domain scores were imputed by last observation carried
forward method. The QoL domain scores were converted
to a unit scale, range 0–1, with a higher score indicating
improved QoL. The conversion was implemented with a
linear affine transformation of original score according
to Ware et. al. Each subject’s QADFS was computed as
the sum of the product QoL weights and the duration for
which the patient experienced that level of QoL. These
QADFS times were then analyzed with Kaplan-Meier
methodology. In order to analyze the effect of adminis-
trative censoring on the results an area under the curve
analysis for each QoL domain was implemented with the
assumption of equal length of follow-up (365 days). RE-
SULTS: The mean QADFS were estimated and compared
amongst the three treatment groups. These comparisons
yielded results that were robust to the choice of QoL do-
mains and the length of follow-up. CONCLUSIONS: Multi-
dimensional QoL instruments may be used to provide a
summary index for assessing the response of novel inter-
ventions for cancer patients. It accounts for patient’s QoL
for the duration of the trial unlike the traditional (e.g.,
ANOVA) methods of analyses.
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OBJECTIVE: Effective antisecretory drugs are available
to treat GERD, and result in dramatic improvement of
pyrosis over placebo. Assessing a similar improvement of
HRQL would appear of value. METHOD: A critical ap-
praisal of published controlled trials was performed us-
ing a checklist. RESULTS: Although trials comparing
proton pump inhibitors (PPI) to placebo or to H2-block-
ers or cisapride showed a clinically significant difference
in the rate of complete relief of pyrosis, none was able to
show a clear and unbiased HRQL improvement. For
each trial, several or all of the following issues that may
help one to have confidence in study results are not pre-
sented or are missing: justification of the choice of ques-
tionnaires; hypotheses of changes in HRQL scores and
power estimation (even if HRQL assessment is a second-
ary endpoint); justification of the use of several question-
naires (are they covering different concepts?); statistical
analysis plan; description and imputation of missing data,
and intent to treat analysis (e.g. 408 patients among 599
randomized in a trial are analyzed for HRQL with no ex-
planation about missing data); adjustment for multiple sta-
tistical comparisons; presentation of all the scores. Generic
questionnaires (Psychological General Well Being is the
most frequently used) result most often in non significant
differences or findings without clinical significance (effect
size  0.30). This raises the uncertainty of questionnaire
responsiveness, knowing that pyrosis is largely improved
and that the sample size of trials ranges from 300 to 800.
Using the specific questionnaire, Gastrointestinal Symp-
tom Rating Scale, leads to significant results, but it may be
argued that this questionnaire is not simply a symptom
scale, because only two items on the questionnaire concern
bother about pyrosis and regurgitation. CONCLUSION:
There is concern to conclude that despite a large improve-
ment of pyrosis, especially with PPI, there is no definite
demonstration that HRQL is improved in GERD.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. The objective of this study is
to describe the development and initial testing of a new
patient self-report instrument, the Patient Assessment of
Upper GastroIntestinal Disorders-Symptom Severity In-
dex (PAGI-SYM) in subjects with gastroesophageal re-
flux disease (GERD) or dyspepsia. METHODS: Instru-
ment content was based on an extensive review of the
published literature and interviews with patients and cli-
nicians. A sample of 448 persons with GERD (249) or
dyspepsia (199) were identified and recruited from a
large population survey. Using telephone interviews, sub-
jects completed the PAGI-SYM, the SF-36, and a measure
of patient-rated change in GI-related symptoms, the
Overall Treatment Effect Scale (OTE). Two-week repro-
ducibility was evaluated in 68 subjects. RESULTS: The
37-item PAGI-SYM is comprised of 6 subscales: heart-
burn, reflux/regurgitation, nausea/vomiting, abdominal
pain, bloating/early satiety, and other symptoms. Sub-
scale internal consistency reliability was good (alpha 
0.74 to 0.92) with the exception of the two-item sub-
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scale, other (alpha  0.45); total score alpha levels were
excellent (0.95). Item correlations by subscale were in the
predicted direction; all were significant (r  0.29 to 0.77;
P  .001). Correlations between PAGI-SYM total and
subscale scores and SF-36 PCS and MCS scores were in
the predicted direction; all were significant (r  0.28 to
0.64; P  .0001). CONCLUSIONS: Results suggest the
PAGI-SYM is internally consistent with evidence of con-
tent and construct validity. Further research on the in-
strument’s reproducibility, sensitivity to change and the
definition of clinically-meaningful change in GERD and
dyspepsia symptoms is needed before use in clinical studies.
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OBJECTIVE: To calculate the break-even point as the
number of years after Laparoscopic Nissen fundoplica-
tion surgery where the surgery’s costs are equivalent to
the costs associated with omeprazole maintenance ther-
apy for patients with severe gastroesophageal reflux dis-
ease (GERD). METHODS: A Markov decision analytic
model was developed to estimate the direct medical costs
of each alternative for treating patients with severe GERD.
The payer perspective was utilized and a literature review
was conducted to identify the direct costs associated with
each approach. The probabilities used in the model were
estimated from published clinical trials. The Markov
model cycle was set equal to one year and the break-even
point was identified as the year in which the expected
values of the costs of each treatment were equal. Sensitiv-
ity analyses were performed. RESULTS: The break-even
point of the two therapies is approximately 12 years. By
subtracting 12 years from the average US life expectancy,
the break-even age is 64 years in which the costs of surgi-
cal treatment for persons under the age of 64 is less than
omeprazole for the remaining years of life. The results of
the sensitivity analyses will be reported. DISCUSSION:
This study provides evidence that Laparoscopic Nissen
fundoplication becomes a cost saving approach relative
to omeprazole therapy when omeprazole therapy is ex-
pected to last more than 12 years. This model assumes
omeprazole therapy is taken continuously over a pa-
tient’s lifetime to treat severe GERD and assumes that
successful surgery does not require maintenance omepra-
zole and lasts a patient’s lifetime. This procedure is a rel-
atively new technique and there is no long-term data on
the success rate. The standard prognosis of success for
the surgery used by gastroenterologists has been 10 years.
The surgical procedure may not be cost saving if the suc-
cess rate declines after 10 years. 
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OBJECTIVE: In the new Dutch General-Practitioner’s
guidelines, Helicobacter pylori (Hp) eradication is indi-
cated for patients with peptic ulcer disease (ulcus duodeni
and ulcus ventriculli). Pharmacotherapy for Hp-eradica-
tion comprises a combination of an antibiotic and a pro-
ton-pump inhibitor (PPI) or a bismuth preparation. Our
objective is to estimate gastrointestinal drug utilization
and related costs prior and post Hp-eradication. METH-
ODS: For the analysis we used a regional pharmacists’
database in the North of the Netherlands (“Interaction
Database”; total population: 130,000; period covered:
1994–98). We selected all patients with two prescriptions
on one day from the same doctor: one prescription for
antibiotics and one for PPI. In total 1210 potential eradi-
cations were found. Over 95% of the patients received at
least one of the following combinations: (i) PPI and amox-
icillin; (ii) PPI, clarithromycin and metronidazole; (iii)
PPI, clarithromycin and amoxicillin. RESULTS: Prelimi-
nary results indicate that in the four months prior to
eradication, 30% of the patients were on ranitidine main-
tenance therapy and 25% used PPIs, but 45% used nei-
ther. Costs of PPIs amount to approximately €500 per
patient in the year prior to eradication. Post-Hp-eradica-
tion results indicate that in the year after eradication,
costs per patient for PPIs decrease to approximately
€250. Updated results, comprising data for 1999 as well,
will be presented at the conference. CONCLUSIONS:
Preliminary results suggest that a significant share of Hp-
eradications occur in patients not using PPIs or raniti-
dine. Furthermore, on the short-term, costs per patient per
year for PPIs are reduced by 50% through Hp-eradication.
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